secwatch.observer — SEC 8-K summary
======================================

Issuer:     60 DEGREES PHARMACEUTICALS, INC. (SXTP)
CIK:        0001946563
Form:       8-K
Filed at:   2025-01-28T23:59:59+00:00
Accession:  0001213900-25-007529
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

60 Degrees Pharma announces IRB approval for Phase II study of tafenoquine in chronic babesiosis
--------------------------------------------------------------------------------

- IRB-approved open-label Phase II study (NCT06656351) evaluating tafenoquine for chronic babesiosis.
- Patient enrollment expected to begin in Q3 2025; participants must have >6 months functional impairment.
- Company estimates cumulative addressable market of >400,000 patients through end of U.S. patent protection in 2035.
- No approved treatment currently exists for chronic babesiosis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1946563/000121390025007529/0001213900-25-007529-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1946563/000121390025007529/ea0228966-8k_60degrees.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-007529

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer